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Supplementary Figure 1
Supplementary Fig 1. Representative clinical timeline of the index autopsy case, demonstrating rapid
progression from the first appearance of metastatic disease. The volume changes of target lesions
between interval CTs performed 5 weeks apart are shown, with the follow-up imaging taken two weeks
after the completion of whole-brain radiotherapy. This showed only minimal intracranial, but extensive
extracranial disease progression.
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Supplementary Figure 2
Supplementary Fig 2. Sample-level phylogenetic tree for the index autopsy case. Each tree represents a
subtree of the overall phylogenetic tree (Fig. 2D) including just those subclones seen within that particular
sample. However in doing this we were able to segregate the samples based on their respective clonal
lineages. We observed two clear lineages, representing distinct waves of metastatic seeding depicted here
as the lineage 1 and 2 emanating from clusters B (light green) and clusters D (red) respectively. Dotted ovals
represent evidence for polyclonal seeding. Subclones within each oval are found with differing CCFs in 2 or
more samples.
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Supplementary Fig 3. CCF distribution plot for whole-exome sequenced patient
MultiSite_WES_Patient1. Rows reflect samples and columns reflect alphabetically and
colour-coded mutation clusters (number of SNVs within each cluster is indicated at the top).
This shows that clusters B (yellow) and F (green) were clonal in mutually exclusive samples
and represent mutually exclusive clonal phylogenies at the first bifurcation of the
phylogenetic tree.
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Supplementary Figure 4
Supplementary Fig 4. Sample-level phylogenetic tree for multi-site whole-exome sequenced cases. The
respective branched lineages are depicted for each patient. Dotted ovals represent evidence for polyclonal
seeding. Subclones within each oval are found with differing CCFs in 2 or more samples. Only two patients
(MultiSite_WES_Patient3 and MultiSite_WES_Patient4) displayed polyclonal seeding.
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Supplementary Fig 5. Mutational signatures for all SNVs from the index autopsy case. Shows the
mutational profile using the conventional 96 mutation type classification as described by Alexandrov and
colleagues31,49. This classification is based on the six substitution subtypes: C>A, C>G, C>T, T>A, T>C, and
T>G. Further, each of the substitutions is examined by incorporating information on the bases immediately
5’ and 3’ to each mutated base generating 96 possible mutation types. Here we show the signature profiles
including all SNVs from all 13 WGS metastases which as expected, were dominated by signature 7.
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Supplementary Fig 6. Mutational signatures from the index autopsy case. A) Here we show the mutational
profiles including; all truncal SNVs in the tree (n~107,000 SNVs) and all non-truncal SNVs (from the six
mutation clusters B-F) in the tree (n=622 SNVs). B) The Global NMF signatures shown represent the ‘best fit’
signatures across all SNVs and the individual percentages for each signature is the proportion which that
signature represents. The cosine similarity reports how closely these signatures together mirror the context
of all SNVs within that cluster group. As expected, the mutational signature for all truncal SNVs is dominated
by signature 7 (90% of SNVs are represented by this signature) whilst this is entirely absent from the non-
truncal clones, which are represented by the APOBEC mutational signatures (2 & 13). The non-highlighted
signatures (1, 5 and 40) shown in black represent relatively featureless (“flat”) oncogenic signatures found in
most cancer types and do-not as yet define any distinguishing biological processes49.
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Supplementary Fig 7. Differential expression and principal component analyses from the index autopsy
case. A) Principal component analysis (PCA) of single sample gene-set enrichment (ssGSEA) using the
hallmark gene sets (see Methods)51. A similar pattern of regional separation (represented in Fig. 4A) was
observed between the brain and lung metastases, which again are separated from the corresponding
patient-matched normal organ control samples. Samples are circled using a kernel density estimation. B)
Principal component feature loadings (magnitude and direction) of (A) are shown in the variables factor
map. Each co-ordinate in (B) reflects the correlation coefficient of the biological process to principal
components 1 (x-axis) and 2 (y-axis) from (A). Vectors are coloured according to the major biological
classification of Hallmark gene sets. This revealed that PC2 (on the y-axis), explaining the variation between
the tumour and normal samples (represented by circles and triangles in (A) respectively), is primarily
represented by the up-regulation of oncogenic processes highlighted with a red arrow pointing
(downwards) towards the tumour samples. C) Volcano plot of the genes differentially expressed between
the brain metastases (n=5) versus the patient-matched normal tissue (one sample from brain and lung
respectively, n=2). Each dot represents one gene, dots above the dotted line are considered statistically
significant (FDR-adjusted p-value <0.005 calculated in limma, see methods) and are shaded according to
fold-change cut-offs (log fold-change < -1 coloured in red, and log fold-change >1 in blue). D) Volcano plot of
the genes differentially expressed between the brain (n=5) versus lung metastases (n=4). Dots represent
genes, coloured in the same format as (C). FDR-corrected p-values are calculated in limma, see methods.
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Supplementary Fig 8. Simulations of phylogenetic tree reconstructions from the index autopsy case
with variable subclonal heterogeneity.
Supplementary Table 1. Summary of key clinical and sample details relating to the index autopsy case. The raw sequencing files and variant/CNV calls are all deposited in data availability.
Patient MelResist_PatientID Sex Melanoma subtype
Date of initial 
melanoma 
diagnosis
TSTAGE (at 
initial 
melanoma 
diagnosis)
NSTAGE (at 
initial 
melanoma 
diagnosis)
MSTAGE (at 
initial 
melanoma 
diagnosis)
Date of trial 
registration
Number of lines 
of therapy
Treatment 
name
Treatment start 
date
Treatment end 
date WGS_SampleID AffySampleID Tumour/Normal Sample_resection_date Sample_type Site Depth Purity_Estimate
Index_autopsy_case 01_123 Male Cutaneous 07/2012 T2a N0 M0 10/2017 1 Whole-brain RT 07/2017 '07/2017 PD38258a PR38258a Tumour 09/2017 Brain Brain_right_superior_frontal_gyrus 33.5134 0.94
Index_autopsy_case 01_123 Male Cutaneous PD38258b NA Normal NA Buffy coat Germline_buffy_coat 37.9218 NA
Index_autopsy_case 01_123 Male Cutaneous PD38258c PR38258c Tumour 09/2017 Brain Brain_right_frontal 36.21725 0.728
Index_autopsy_case 01_123 Male Cutaneous PD38258d PR38258d Tumour 09/2017 Brain Brain_left_superior_parietal 37.81692 0.856
Index_autopsy_case 01_123 Male Cutaneous PD38258e PR38258e Tumour 09/2017 Brain Brain_left_posterior_parietal 36.1521 0.821
Index_autopsy_case 01_123 Male Cutaneous PD38258f PR38258f Tumour 09/2017 Brain Brain_right_parietal 41.0643 0.857
Index_autopsy_case 01_123 Male Cutaneous PD38258h PR38258h Tumour 09/2017 Lung Lung_right_lower_lobe 43.87209 0.511
Index_autopsy_case 01_123 Male Cutaneous PD38258i PR38258i Tumour 09/2017 Lung Lung_left_lower_lobe 41.63439 0.89
Index_autopsy_case 01_123 Male Cutaneous PD38258j PR38258j Tumour 09/2017 Lung Lung_left_upper_lobe1 33.03544 0.883
Index_autopsy_case 01_123 Male Cutaneous PD38258k PR38258k Tumour 09/2017 Lung Lung_left_upper_lobe2 39.93535 0.709
Index_autopsy_case 01_123 Male Cutaneous PD38258m PR38258m Tumour 09/2017 Liver Liver_right_lobe 36.84432 0.884
Index_autopsy_case 01_123 Male Cutaneous PD38258o NA Tumour 09/2017 L hilar lymph node LN_left_hilar 39.42053 0.422
Index_autopsy_case 01_123 Male Cutaneous PD38258r NA Tumour 09/2017 Stomach Stomach_greater_omentum 38.36801 0.586
Index_autopsy_case 01_123 Male Cutaneous PD38258t PR38258t Tumour 09/2017 Heart Heart_right_atrium 40.30025 0.823
Index_autopsy_case 01_123 Male Cutaneous PD38258u NA Tumour 07/2012 Primary Primary_anterior_chest_wall1 NA NA
Index_autopsy_case 01_123 Male Cutaneous PD38258v NA Tumour 07/2012 Primary Primary_anterior_chest_wall2 NA NA
Supplementary Table 2. Summary of key clinical and sample details relating to the multisite whole-exome sequenced cases. The raw sequencing files and variant/CNV calls are all deposited in data availability.
Patient MelResist_PatientID Sex Melanoma subtype
Date of initial 
melanoma 
diagnosis
TSTAGE (at initial 
melanoma 
diagnosis)
NSTAGE (at initial 
melanoma 
diagnosis)
MSTAGE (at initial 
melanoma 
diagnosis)
Date of trial registration Number of lines of therapy Treatment name Treatment start date Treatment end date WES_SampleID Tumour/Normal Sample_resection_date Sample_type Site
Target_Region_Coverage_AfterPC
RDupRemoval
MultiSite_WES_Patient1 MR01_034 Female Acral 12/2003 T4b N0 M0 03/2014 2 Roche/RAF/MEK 
Inhibitor
07/2010 09/2011 PD21941i Tumour 06/2015 Distant skin/subcutanoues Subcutaneous nodule left 
inframammary fold
34.5
MultiSite_WES_Patient1 MR01_034 Female Acral Ipilimumab 10/2011 12/2011 PD21941f Tumour 04/2015 Distant skin/subcutanoues Right labia deposit 37.4
MultiSite_WES_Patient1 MR01_034 Female Acral PD21941d Tumour 09/2014 Distant lymph node Left groin node 39.3
MultiSite_WES_Patient1 MR01_034 Female Acral PD21941e Tumour 04/2015 Distant skin/subcutanoues Right shoulder deposit 53.7
MultiSite_WES_Patient1 MR01_034 Female Acral PD21941h Tumour 04/2015 Distant lymph node Right axilla 61.8
MultiSite_WES_Patient1 MR01_034 Female Acral PD21941a Tumour 03/2014 Distant skin/subcutanoues Left Lower limb 67.8
MultiSite_WES_Patient1 MR01_034 Female Acral PD31210b Normal NA Normal Normal 107.5
MultiSite_WES_Patient2 MR01_014 Male Cutaenous 07/2012 T1b 11/2014 0 None PD13325b Normal 11/2012 Normal Normal 63.2
MultiSite_WES_Patient2 MR01_014 Male Cutaenous PD13325a Tumour 11/2012 Primary Right forearm 54
MultiSite_WES_Patient2 MR01_014 Male Cutaenous PD13325c Tumour 08/2014 Distant skin/subcutanoues Right head 94.7
MultiSite_WES_Patient3 MR01_020 Male Cutaenous 07/2012 T4b N0 M0 03/2013 3 Vemurafenib 03/2013 05/2013 PD15682b Normal NA Normal Normal 74.2
MultiSite_WES_Patient3 MR01_020 Male Cutaenous Ipilimumab 05/2013 '08/2013 PD15682c Tumour 05/2013 Regional lymph node  Axillary lymph node 64.8
MultiSite_WES_Patient3 MR01_020 Male Cutaenous Dacarbazine, Cisplatin, 
Vinblastine
11/2008 12/2009 PD15682a Tumour 03/2013 Regional lymph node Left axilla lymph node 68.7
MultiSite_WES_Patient4 MR01_003 Male Cutaenous 03/2004 T4a N1b M1a 02/2012 4 Dacarbazine 04/2004 07/2004 PD13315b Normal NA Normal Normal 71.9
MultiSite_WES_Patient4 MR01_003 Male Cutaenous Ipilimumab 09/2011 11/2011 PD13315c Tumour 02/2012 Distant skin/subcutanoues Left back 42.2
MultiSite_WES_Patient4 MR01_003 Male Cutaenous Vemurafenib 02/2012 11/2013 PD13315a Tumour 02/2012 Distant skin/subcutanoues Right chest 44.5
MultiSite_WES_Patient4 MR01_003 Male Cutaenous Nivolumab 12/2013 05/2016
MultiSite_WES_Patient5 MR01_010 Male Cutaenous 10/2004 T2b N0 M0 07/2012 3 Post-op RT 04/2010 04/2010 PD13615a2 Tumour 07/2012 Regional skin/subcutaneous Skin unspecified 33.3
MultiSite_WES_Patient5 MR01_010 Male Cutaenous Vemurafenib 07/2012 01/2013 PD13615b Normal NA Normal Normal 35.1
MultiSite_WES_Patient5 MR01_010 Male Cutaenous Ipilimumab 01/2013 02/2013 PD13615d Tumour 01/2013 Regional skin/subcutaneous Left lower back 48.9
MultiSite_WES_Patient6 MR01_012 Male Cutaenous 01/2010 TX N0 11/2012 1 Dabrafenib + trametinib 10/2012 06/2013 PD13323d Tumour 10/2012 Distant lymph node Left groin node 46
MultiSite_WES_Patient6 MR01_012 Male Cutaenous PD13323b Normal NA Normal Normal 79.8
MultiSite_WES_Patient6 MR01_012 Male Cutaenous PD13323e Tumour 04/2013 Distant lymph node Left inguinal node 51.3
MultiSite_WES_Patient7 MR01_004 Male Cutaenous 10/2010 T3b N3 M0 04/2012 5 RT (40Gy/20#) 05/2011 06/2011 PD13316b Normal NA Normal Normal 74.9
MultiSite_WES_Patient7 MR01_004 Male Cutaenous Vemurafenib 04/2012 01/2013 PD13316a Tumour 04/2012 Distant skin/subcutanoues Left posterior ear 42.4
MultiSite_WES_Patient7 MR01_004 Male Cutaenous Ipilimumab 01/2013 03/2013 PD13316d Tumour 05/2013 Distant skin/subcutanoues Left supraclavicular fossa 52.2
MultiSite_WES_Patient7 MR01_004 Male Cutaenous Pazopanib 07/2013 09/2013 PD13316e Tumour 11/2013 Regional skin/subcutaneous Left scalp 63.6
MultiSite_WES_Patient7 MR01_004 Male Cutaenous Dabrafenib + trametinib 11/2013 02/2014
Supplementary tables key
Header Code Explanation
Patient Patient Patient identifier as labelled in this study
MelResist_PatientID MelResist_PatientID Patient code within the clinical trial (Melresist)
Sex Male Male
Sex Female Female
Melanoma subtype Cutaneous Cutaneous/acral primary melanoma subtype
Melanoma subtype Acral
Date of initial melanoma diagnosis Date of initial melanoma diagnosis Date of initial melanoma diagnosis
TSTAGE (at initial melanoma diagnosis) TX Primary tumour cannot be assessed
TSTAGE (at initial melanoma diagnosis) T0 No evidence of primary tumour
TSTAGE (at initial melanoma diagnosis) Tis Melanoma in situ
TSTAGE (at initial melanoma diagnosis)
T1a Melanomas 1.0mm or less without ulceration & mitosis
TSTAGE (at initial melanoma diagnosis)
T1b Melanomas 1.0mm or less with ulceration & mitosis
TSTAGE (at initial melanoma diagnosis) T2a Melanomas 1.01 - 2.0mm without ulceration
TSTAGE (at initial melanoma diagnosis) T2b Melanomas 1.01 - 2.0mm with ulceration
TSTAGE (at initial melanoma diagnosis) T3a Melanomas 2.01 - 4.0mm without ulceration
TSTAGE (at initial melanoma diagnosis) T3b Melanomas 2.01 - 4.0mm with ulceration
TSTAGE (at initial melanoma diagnosis) T4a Melanomas more than 4.0mm without ulceration
TSTAGE (at initial melanoma diagnosis) T4b Melanomas more than 4.0mm with ulceration
NSTAGE (at initial melanoma diagnosis)
NX Patients in whom the regional lymph nodes cannot be assessed
NSTAGE (at initial melanoma diagnosis) N0 No regional lymph node metastasis detected
NSTAGE (at initial melanoma diagnosis)
N1a Melanoma cells in one lymph node with micrometastasis
NSTAGE (at initial melanoma diagnosis)
N1b Melanoma cells in one lymph node with macrometastasis
NSTAGE (at initial melanoma diagnosis)
N2a Melanoma cells in 2 or 3 lymph nodes with micrometastasis
NSTAGE (at initial melanoma diagnosis)
N2b Melanoma cells in 2 or 3 lymph nodes with macrometastasis
NSTAGE (at initial melanoma diagnosis)
N2c
Melanoma cells in 2 or 3 lymph nodes with intransit met(s)/ satellite(s) 
without metastatic nodes
NSTAGE (at initial melanoma diagnosis)
N3
Four or more metastatic lymph nodes, or intransit met(s)/ satellite(s) with 
metastatic nodes
MSTAGE (at initial melanoma diagnosis) M0 No detectable evidence of distant metastasis
MSTAGE (at initial melanoma diagnosis)
M1a Metastasis to skin, subcutaneous, or distant lymph nodes with normal LDH
MSTAGE (at initial melanoma diagnosis) M1b Metastasis to lung with normal LDH
MSTAGE (at initial melanoma diagnosis)
M1c
Metastasis to all other visceral sites with normal LDH or Any distant 
metastasis to any site with elevated LDH
Date of trial registration Date of trial registration Date of trial registration
Number of lines of therapy Number of lines of therapy Number of lines of therapy (up to data extract 15.11.19)
Treatment name Treatment name Treatment name
Treatment start date Treatment start date Treatment start date
Treatment end date Treatment end date Treatment end date
WGS_SampleID WGS_SampleID
Sample IDs for whole-genome sequencing data (index autopsy case only, 
though the two samples from primary tumour were sequenced with custom 
capture pull-down)
WES_SampleID WES_SampleID Sample IDs for whole-exome sequencing data 
AffySampleID AffySampleID Affymetrix sample IDs (index autopsy case only)
Tumour/Normal Tumour Sample is a tumour
Tumour/Normal Normal Sample is normal (germline)
Sample_resection_date Sample_resection_date Date tumour sample was resected from patient
Sample_type Sample_type Type of sample
Site Site Anatomical site of sample
Depth Depth Average depth across the entire whole genome (index autopsy case only)
Purity_Estimate Purity_Estimate Estimate of tumour purity from copy number call (Battenberg, index autopsy case only)
Target_Region_Coverage_AfterPCRDupRem
oval
Target_Region_Coverage_AfterPCRD
upRemoval
Depth after excluding PCR dups, QC failed reads, supplementary and 
secondary read alignments
